Wellington Management Group LLP Sells 18,765,809 Shares of Abbott Laboratories $ABT

Wellington Management Group LLP lessened its stake in Abbott Laboratories (NYSE:ABT) by 69.3% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 8,304,709 shares of the healthcare product maker’s stock after selling 18,765,809 shares during the quarter. Wellington Management Group LLP’s holdings in Abbott Laboratories were worth $753,569,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. MidAtlantic Capital Management Inc. purchased a new stake in Abbott Laboratories in the 4th quarter worth $25,000. Cornerstone Financial Management LLC bought a new stake in shares of Abbott Laboratories in the fourth quarter worth about $25,000. Purpose Unlimited Inc. purchased a new stake in shares of Abbott Laboratories in the fourth quarter worth about $25,000. Portfolio Resources Advisor Group Inc. bought a new position in Abbott Laboratories during the fourth quarter valued at approximately $26,000. Finally, Abound Financial LLC purchased a new position in Abbott Laboratories during the 4th quarter valued at approximately $26,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott shares outperformed the broader market in the latest session, suggesting continued investor support for the diversified healthcare-products company. The move adds to its gains above both its 50-day and 200-day moving averages. Abbott Exceeds Market Returns: Some Facts to Consider
• Neutral Sentiment: A separate market comparison reported that Abbott underperformed its competitors during Tuesday’s trading session. The article did not identify a company-specific operational problem, making the relative weakness more relevant to short-term sentiment than to Abbott’s long-term fundamentals. Abbott Laboratories Stock Underperforms Tuesday
• Neutral Sentiment: Vice President John McCoy Jr. sold 27 shares for approximately $2,958. The transaction reduced his direct holdings by only 0.11%, leaving him with 24,549 shares, so it is too small to represent a meaningful change in insider conviction. SEC Insider Transaction Filing
• Neutral Sentiment: An investor-focused healthcare article mentioned Abbott primarily as the former parent of AbbVie, rather than discussing new developments at ABT. It therefore provides little direct information about Abbott’s near-term earnings or valuation. Abbott Laboratories Company Information

Analyst Ratings Changes

Several brokerages have recently issued reports on ABT. Weiss Ratings raised Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, August 6th. BTIG Research lifted their price objective on shares of Abbott Laboratories from $131.00 to $134.00 and gave the stock a “buy” rating in a research note on Friday, July 17th. Wells Fargo & Company boosted their target price on shares of Abbott Laboratories from $109.00 to $112.00 and gave the stock an “overweight” rating in a report on Friday, July 17th. Citigroup increased their price target on shares of Abbott Laboratories from $108.00 to $112.00 and gave the company a “buy” rating in a report on Friday, July 17th. Finally, TD Cowen boosted their price objective on Abbott Laboratories from $115.00 to $135.00 and gave the stock a “buy” rating in a research note on Tuesday, August 25th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, Abbott Laboratories presently has an average rating of “Moderate Buy” and a consensus target price of $119.50.

Abbott Laboratories Trading Down 1.5%

ABT stock opened at $108.81 on Friday. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $137.49. The stock has a market capitalization of $188.28 billion, a price-to-earnings ratio of 35.21, a price-to-earnings-growth ratio of 2.05 and a beta of 0.59. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. The firm’s fifty day simple moving average is $104.14 and its two-hundred day simple moving average is $100.06.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The firm had revenue of $12.59 billion during the quarter, compared to analysts’ expectations of $12.52 billion. During the same period in the previous year, the company earned $1.26 EPS. The firm’s revenue for the quarter was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, analysts anticipate that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th were paid a dividend of $0.63 per share. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. Abbott Laboratories’s dividend payout ratio is currently 81.55%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.